BioXcel Therapeutics Inc. (BTAI)
BioXcel Therapeutics Statistics
Share Statistics
BioXcel Therapeutics has 49.63M shares outstanding. The number of shares has increased by 47.57% in one year.
| Shares Outstanding | 49.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 21.81% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 41.30M |
| Failed to Deliver (FTD) Shares | 100 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 347.08K, so 0.7% of the outstanding shares have been sold short.
| Short Interest | 347.08K |
| Short % of Shares Out | 0.7% |
| Short % of Float | 0.84% |
| Short Ratio (days to cover) | 0.93 |
Valuation Ratios
The PE ratio is -0.48 and the forward PE ratio is -0.4.
| PE Ratio | -0.48 |
| Forward PE | -0.4 |
| PS Ratio | 62.27 |
| Forward PS | 1.5 |
| PB Ratio | -1.52 |
| P/FCF Ratio | -0.55 |
| PEG Ratio | n/a |
Enterprise Valuation
BioXcel Therapeutics Inc. has an Enterprise Value (EV) of 122.09M.
| EV / Earnings | -0.68 |
| EV / Sales | 88.47 |
| EV / EBITDA | -0.74 |
| EV / EBIT | -0.71 |
| EV / FCF | -0.79 |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of -1.79.
| Current Ratio | 2.65 |
| Quick Ratio | 2.57 |
| Debt / Equity | -1.79 |
| Total Debt / Capitalization | 225.92 |
| Cash Flow / Debt | -1.53 |
| Interest Coverage | -12.9 |
Financial Efficiency
Return on equity (ROE) is 3.17% and return on capital (ROIC) is -382.79%.
| Return on Equity (ROE) | 3.17% |
| Return on Assets (ROA) | -2.43% |
| Return on Capital (ROIC) | -382.79% |
| Revenue Per Employee | 18.65K |
| Profits Per Employee | -2.42M |
| Employee Count | 74 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.63 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -89.21% in the last 52 weeks. The beta is 0.29, so BioXcel Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.29 |
| 52-Week Price Change | -89.21% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 46.43 |
| Average Volume (20 Days) | 1.48M |
Income Statement
In the last 12 months, BioXcel Therapeutics had revenue of 1.38M and earned -179.05M in profits. Earnings per share was -6.15.
| Revenue | 1.38M |
| Gross Profit | 120.00K |
| Operating Income | -171.78M |
| Net Income | -179.05M |
| EBITDA | -165.42M |
| EBIT | -171.78M |
| Earnings Per Share (EPS) | -6.15 |
Balance Sheet
The company has 65.22M in cash and 101.38M in debt, giving a net cash position of -36.16M.
| Cash & Cash Equivalents | 65.22M |
| Total Debt | 101.38M |
| Net Cash | -36.16M |
| Retained Earnings | -590.60M |
| Total Assets | 48.89M |
| Working Capital | 22.23M |
Cash Flow
In the last 12 months, operating cash flow was -155.01M and capital expenditures -20.00K, giving a free cash flow of -155.03M.
| Operating Cash Flow | -155.01M |
| Capital Expenditures | -20.00K |
| Free Cash Flow | -155.03M |
| FCF Per Share | -5.32 |
Margins
Gross margin is 8.7%, with operating and profit margins of -12.45K% and -12.97K%.
| Gross Margin | 8.7% |
| Operating Margin | -12.45K% |
| Pretax Margin | -12.97K% |
| Profit Margin | -12.97K% |
| EBITDA Margin | -11.99K% |
| EBIT Margin | -12.45K% |
| FCF Margin | -11.23K% |
Dividends & Yields
BTAI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1662.16% |
| FCF Yield | -844.47% |
Analyst Forecast
The average price target for BTAI is $3, which is 710.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 710.8% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -21.45 |
| Piotroski F-Score | 1 |